Browsing by Author "Odemyr M."

Now showing 1 - 7 of 7
  • No Thumbnail Available
    Item
    Prioritizing research challenges and funding for allergy and asthma and the need for translational research—The European Strategic Forum on Allergic Diseases
    (Blackwell Publishing Ltd, 2019) Agache I.; Annesi-Maesano I.; Bonertz A.; Branca F.; Cant A.; Fras Z.; Ingenrieth F.; Namazova-Baranova L.; Odemyr M.; Spanevello A.; Vieths S.; Yorgancioglu A.; Alvaro-Lozano M.; Barber Hernandez D.; Chivato T.; Del Giacco S.; Diamant Z.; Eguiluz-Gracia I.; van Wijk R.G.; Gevaert P.; Graessel A.; Hellings P.; Hoffmann-Sommergruber K.; Jutel M.; Lau S.; Lauerma A.; Maria Olaguibel J.; O'Mahony L.; Ozdemir C.; Palomares O.; Pfaar O.; Sastre J.; Scadding G.; Schmidt-Weber C.; Schmid-Grendelmeier P.; Shamji M.; Skypala I.; Spinola M.; Spranger O.; Torres M.; Vereda A.; Bonini S.
    The European Academy of Allergy and Clinical Immunology (EAACI) organized the first European Strategic Forum on Allergic Diseases and Asthma. The main aim was to bring together all relevant stakeholders and decision-makers in the field of allergy, asthma and clinical Immunology around an open debate on contemporary challenges and potential solutions for the next decade. The Strategic Forum was an upscaling of the EAACI White Paper aiming to integrate the Academy's output with the perspective offered by EAACI's partners. This collaboration is fundamental for adapting and integrating allergy and asthma care into the context of real-world problems. The Strategic Forum on Allergic Diseases brought together all partners who have the drive and the influence to make positive change: national and international societies, patients’ organizations, regulatory bodies and industry representatives. An open debate with a special focus on drug development and biomedical engineering, big data and information technology and allergic diseases and asthma in the context of environmental health concluded that connecting science with the transformation of care and a joint agreement between all partners on priorities and needs are essential to ensure a better management of allergic diseases and asthma in the advent of precision medicine together with global access to innovative and affordable diagnostics and therapeutics. © 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
  • No Thumbnail Available
    Item
    Management of anaphylaxis due to COVID-19 vaccines in the elderly
    (John Wiley and Sons Inc, 2021) Bousquet J.; Agache I.; Blain H.; Jutel M.; Ventura M.T.; Worm M.; Del Giacco S.; Benetos A.; Bilo B.M.; Czarlewski W.; Abdul Latiff A.H.; Al-Ahmad M.; Angier E.; Annesi-Maesano I.; Atanaskovic-Markovic M.; Bachert C.; Barbaud A.; Bedbrook A.; Bennoor K.S.; Berghea E.C.; Bindslev-Jensen C.; Bonini S.; Bosnic-Anticevich S.; Brockow K.; Brussino L.; Camargos P.; Canonica G.W.; Cardona V.; Carreiro-Martins P.; Carriazo A.; Casale T.; Caubet J.-C.; Cecchi L.; Cherubini A.; Christoff G.; Chu D.K.; Cruz A.A.; Dokic D.; El-Gamal Y.; Ebisawa M.; Eberlein B.; Farrell J.; Fernandez-Rivas M.; Fokkens W.J.; Fonseca J.A.; Gao Y.; Gavazzi G.; Gawlik R.; Gelincik A.; Gemicioğlu B.; Gotua M.; Guérin O.; Haahtela T.; Hoffmann-Sommergruber K.; Hoffmann H.J.; Hofmann M.; Hrubisko M.; Illario M.; Irani C.; Ispayeva Z.; Ivancevich J.C.; Julge K.; Kaidashev I.; Khaitov M.; Knol E.; Kraxner H.; Kuna P.; Kvedariene V.; Lauerma A.; Le L.T.T.; Le Moing V.; Levin M.; Louis R.; Lourenco O.; Mahler V.; Martin F.C.; Matucci A.; Milenkovic B.; Miot S.; Montella E.; Morais-Almeida M.; Mortz C.G.; Mullol J.; Namazova-Baranova L.; Neffen H.; Nekam K.; Niedoszytko M.; Odemyr M.; O’Hehir R.E.; Okamoto Y.; Ollert M.; Palomares O.; Papadopoulos N.G.; Panzner P.; Passalacqua G.; Patella V.; Petrovic M.; Pfaar O.; Pham-Thi N.; Plavec D.; Popov T.A.; Recto M.T.; Regateiro F.S.; Reynes J.; Roller-Winsberger R.E.; Rolland Y.; Romano A.; Rondon C.; Rottem M.; Rouadi P.W.; Salles N.; Samolinski B.; Santos A.F.; S Sarquis F.; Sastre J.; M. G. A. Schols J.; Scichilone N.; Sediva A.; Shamji M.H.; Sheikh A.; Skypala I.; Smolinska S.; Sokolowska M.; Sousa-Pinto B.; Sova M.; Stelmach R.; Sturm G.; Suppli Ulrik C.; Todo-Bom A.M.; Toppila-Salmi S.; Tsiligianni I.; Torres M.; Untersmayr E.; Urrutia Pereira M.; Valiulis A.; Vitte J.; Vultaggio A.; Wallace D.; Walusiak-Skorupa J.; Wang D.-Y.; Waserman S.; Yorgancioglu A.; Yusuf O.M.; Zernotti M.; Zidarn M.; Chivato T.; Akdis C.A.; Zuberbier T.; Klimek L.
    Older adults, especially men and/or those with diabetes, hypertension, and/or obesity, are prone to severe COVID-19. In some countries, older adults, particularly those residing in nursing homes, have been prioritized to receive COVID-19 vaccines due to high risk of death. In very rare instances, the COVID-19 vaccines can induce anaphylaxis, and the management of anaphylaxis in older people should be considered carefully. An ARIA-EAACI-EuGMS (Allergic Rhinitis and its Impact on Asthma, European Academy of Allergy and Clinical Immunology, and European Geriatric Medicine Society) Working Group has proposed some recommendations for older adults receiving the COVID-19 vaccines. Anaphylaxis to COVID-19 vaccines is extremely rare (from 1 per 100,000 to 5 per million injections). Symptoms are similar in younger and older adults but they tend to be more severe in the older patients. Adrenaline is the mainstay treatment and should be readily available. A flowchart is proposed to manage anaphylaxis in the older patients. © 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
  • No Thumbnail Available
    Item
    ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy
    (John Wiley and Sons Inc, 2021) Bousquet J.; Pfaar O.; Agache I.; Bedbrook A.; Akdis C.A.; Canonica G.W.; Chivato T.; Al-Ahmad M.; Abdul Latiff A.H.; Ansotegui I.J.; Bachert C.; Baharuddin A.; Bergmann K.-C.; Bindslev-Jensen C.; Bjermer L.; Bonini M.; Bosnic-Anticevich S.; Bosse I.; Brough H.A.; Brussino L.; Calderon M.A.; Caraballo L.; Cardona V.; Carreiro-Martins P.; Casale T.; Cecchi L.; Cepeda Sarabia A.M.; Chkhartishvili E.; Chu D.K.; Cirule I.; Cruz A.A.; Czarlewski W.; del Giacco S.; Demoly P.; Devillier P.; Dokic D.; Durham S.L.; Ebisawa M.; El-Gamal✝ Y.; Emuzyte R.; Gamkrelidze A.; Fauquert J.L.; Fiocchi A.; Fokkens W.J.; Fonseca J.A.; Fontaine J.-F.; Gawlik R.; Gelincik A.; Gemicioglu B.; Gereda J.E.; Gerth van Wijk R.; Gomez R.M.; Gotua M.; Grisle I.; Guzmán M.-A.; Haahtela T.; Halken S.; Heffler E.; Hoffmann-Sommergruber K.; Hossny E.; Hrubiško M.; Irani C.; Ivancevich J.C.; Ispayeva Z.; Julge K.; Kaidashev I.; Kalayci O.; Khaitov M.; Klimek L.; Knol E.; Kowalski M.L.; Kraxner H.; Kull I.; Kuna P.; Kvedariene V.; Kritikos V.; Lauerma A.; Lau S.; Laune D.; Levin M.; Larenas-Linnemann D.E.; Lodrup Carlsen K.C.; Lombardi C.; Lourenço O.M.; Mahboub B.; Malling H.-J.; Manning P.; Marshall G.D.; Melén E.; Meltzer E.O.; Miculinic N.; Milenkovic B.; Moin M.; Montefort S.; Morais-Almeida M.; Mortz C.G.; Mösges R.; Mullol J.; Namazova Baranova L.; Neffen H.; Nekam K.; Niedoszytko M.; Odemyr M.; O'Hehir R.E.; Ollert M.; O'Mahony L.; Ohta K.; Okamoto Y.; Okubo K.; Pajno G.B.; Palomares O.; Palkonen S.; Panzner P.; G Papadopoulos N.; Park H.-S.; Passalacqua G.; Patella V.; Pawankar R.; Pham-Thi N.; Plavec D.; Popov T.A.; Recto M.; Regateiro F.S.; Riggioni C.; Roberts G.; Rodriguez-Gonzales M.; Rosario N.; Rottem M.; Rouadi P.W.; Ryan D.; Samolinski B.; Sanchez-Borges✝ M.; Serpa F.S.; Sastre J.; Scadding G.K.; Shamji M.H.; Schmid-Grendelmeier P.; Schünemann H.J.; Sheikh A.; Scichilone N.; Sisul J.C.; Sofiev M.; Solé D.; Sooronbaev T.; Soto-Martinez M.; Soto-Quiros M.; Sova M.; Schwarze J.; Skypala I.; Suppli-Ulrik C.; Taborda-Barata L.; Todo-Bom A.; Torres M.J.; Valentin-Rostan M.; Tomazic P.-V.; Valero A.; Toppila-Salmi S.; Tsiligianni I.; Untersmayr E.; Urrutia-Pereira M.; Valiulis A.; Valovirta E.; Vandenplas O.; Ventura M.T.; Vichyanond P.; Wagenmann M.; Wallace D.; Walusiak-Skorupa J.; Wang D.Y.; Waserman S.; Wong G.W.K.; Yorgancioglu A.; Yusuf O.M.; Zernotti M.; Zhang L.; Zidarn M.; Zuberbier T.; Jutel M.
    [No abstract available]
  • No Thumbnail Available
    Item
    ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice
    (John Wiley and Sons Inc, 2021) Bousquet J.; Anto J.M.; Bachert C.; Haahtela T.; Zuberbier T.; Czarlewski W.; Bedbrook A.; Bosnic-Anticevich S.; Walter Canonica G.; Cardona V.; Costa E.; Cruz A.A.; Erhola M.; Fokkens W.J.; Fonseca J.A.; Illario M.; Ivancevich J.-C.; Jutel M.; Klimek L.; Kuna P.; Kvedariene V.; Le L.T.T.; Larenas-Linnemann D.E.; Laune D.; Lourenço O.M.; Melén E.; Mullol J.; Niedoszytko M.; Odemyr M.; Okamoto Y.; Papadopoulos N.G.; Patella V.; Pfaar O.; Pham-Thi N.; Rolland C.; Samolinski B.; Sheikh A.; Sofiev M.; Suppli Ulrik C.; Todo-Bom A.; Tomazic P.-V.; Toppila-Salmi S.; Tsiligianni I.; Valiulis A.; Valovirta E.; Ventura M.-T.; Walker S.; Williams S.; Yorgancioglu A.; Agache I.; Akdis C.A.; Almeida R.; Ansotegui I.J.; Annesi-Maesano I.; Arnavielhe S.; Basagaña X.; D. Bateman E.; Bédard A.; Bedolla-Barajas M.; Becker S.; Bennoor K.S.; Benveniste S.; Bergmann K.C.; Bewick M.; Bialek S.; E. Billo N.; Bindslev-Jensen C.; Bjermer L.; Blain H.; Bonini M.; Bonniaud P.; Bosse I.; Bouchard J.; Boulet L.-P.; Bourret R.; Boussery K.; Braido F.; Briedis V.; Briggs A.; Brightling C.E.; Brozek J.; Brusselle G.; Brussino L.; Buhl R.; Buonaiuto R.; Calderon M.A.; Camargos P.; Camuzat T.; Caraballo L.; Carriazo A.-M.; Carr W.; Cartier C.; Casale T.; Cecchi L.; Cepeda Sarabia A.M.; H. Chavannes N.; Chkhartishvili E.; Chu D.K.; Cingi C.; Correia de Sousa J.; Costa D.J.; Courbis A.-L.; Custovic A.; Cvetkosvki B.; D'Amato G.; da Silva J.; Dantas C.; Dokic D.; Dauvilliers Y.; De Feo G.; De Vries G.; Devillier P.; Di Capua S.; Dray G.; Dubakiene R.; Durham S.R.; Dykewicz M.; Ebisawa M.; Gaga M.; El-Gamal Y.; Heffler E.; Emuzyte R.; Farrell J.; Fauquert J.-L.; Fiocchi A.; Fink-Wagner A.; Fontaine J.-F.; Fuentes Perez J.M.; Gemicioğlu B.; Gamkrelidze A.; Garcia-Aymerich J.; Gevaert P.; Gomez R.M.; González Diaz S.; Gotua M.; Guldemond N.A.; Guzmán M.-A.; Hajjam J.; Huerta Villalobos Y.R.; Humbert M.; Iaccarino G.; Ierodiakonou D.; Iinuma T.; Jassem E.; Joos G.; Jung K.-S.; Kaidashev I.; Kalayci O.; Kardas P.; Keil T.; Khaitov M.; Khaltaev N.; Kleine-Tebbe J.; Kouznetsov R.; Kowalski M.L.; Kritikos V.; Kull I.; La Grutta S.; Leonardini L.; Ljungberg H.; Lieberman P.; Lipworth B.; Lodrup Carlsen K.C.; Lopes-Pereira C.; Loureiro C.C.; Louis R.; Mair A.; Mahboub B.; Makris M.; Malva J.; Manning P.; Marshall G.D.; Masjedi M.R.; Maspero J.F.; Carreiro-Martins P.; Makela M.; Mathieu-Dupas E.; Maurer M.; De Manuel Keenoy E.; Melo-Gomes E.; Meltzer E.O.; Menditto E.; Mercier J.; Micheli Y.; Miculinic N.; Mihaltan F.; Milenkovic B.; Mitsias D.I.; Moda G.; Mogica-Martinez M.-D.; Mohammad Y.; Montefort S.; Monti R.; Morais-Almeida M.; Mösges R.; Münter L.; Muraro A.; Murray R.; Naclerio R.; Napoli L.; Namazova-Baranova L.; Neffen H.; Nekam K.; Neou A.; Nordlund B.; Novellino E.; Nyembue D.; O'Hehir R.; Ohta K.; Okubo K.; Onorato G.L.; Orlando V.; Ouedraogo S.; Palamarchuk J.; Pali-Schöll I.; Panzner P.; Park H.-S.; Passalacqua G.; Pépin J.-L.; Paulino E.; Pawankar R.; Phillips J.; Picard R.; Pinnock H.; Plavec D.; Popov T.A.; Portejoie F.; Price D.; Prokopakis E.P.; Psarros F.; Pugin B.; Puggioni F.; Quinones-Delgado P.; Raciborski F.; Rajabian-Söderlund R.; Regateiro F.S.; Reitsma S.; Rivero-Yeverino D.; Roberts G.; Roche N.; Rodriguez-Zagal E.; Roller-Wirnsberger R.E.; Rosario N.; Romano A.; Rottem M.; Ryan D.; Salimäki J.; Sanchez-Borges M.M.; Sastre J.; Scadding G.K.; Scheire S.; Schmid-Grendelmeier P.; Schünemann H.J.; Sarquis Serpa F.; Shamji M.; Sisul J.-C.; Solé D.; Somekh D.; Sooronbaev T.; Sova M.; Spertini F.; Spranger O.; Stellato C.; Stelmach R.; Thibaudon M.; To T.; Toumi M.; Usmani O.; Valero A.A.; Valenta R.; Valentin-Rostan M.; Pereira M.U.; van der Kleij R.; Van Eerd M.; Vandenplas O.; Vasankari T.; Vaz Carneiro A.; Vezzani G.; Viart F.; Viegi G.; Wallace D.; Wagenmann M.; Wang D.Y.; Waserman S.; Wickman M.; Williams D.M.; Wong G.; Wroczynski P.; Yiallouros P.K.; Yusuf O.M.; Zar H.J.; Zeng S.; Zernotti M.E.; Zhang L.; Shan Zhong N.; Zidarn M.
    Digital anamorphosis is used to define a distorted image of health and care that may be viewed correctly using digital tools and strategies. MASK digital anamorphosis represents the process used by MASK to develop the digital transformation of health and care in rhinitis. It strengthens the ARIA change management strategy in the prevention and management of airway disease. The MASK strategy is based on validated digital tools. Using the MASK digital tool and the CARAT online enhanced clinical framework, solutions for practical steps of digital enhancement of care are proposed. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
  • No Thumbnail Available
    Item
    Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model
    (John Wiley and Sons Inc, 2022) Sousa-Pinto B.; Azevedo L.F.; Sá-Sousa A.; Vieira R.J.; Amaral R.; Klimek L.; Czarlewski W.; Anto J.M.; Bedbrook A.; Kvedariene V.; Ventura M.T.; Ansotegui I.J.; Bergmann K.-C.; Brussino L.; Canonica G.W.; Cardona V.; Carreiro-Martins P.; Casale T.; Cecchi L.; Chivato T.; Chu D.K.; Cingi C.; Costa E.M.; Cruz A.A.; De Feo G.; Devillier P.; Fokkens W.J.; Gaga M.; Gemicioğlu B.; Haahtela T.; Ivancevich J.C.; Ispayeva Z.; Jutel M.; Kuna P.; Kaidashev I.; Kraxner H.; Larenas-Linnemann D.E.; Laune D.; Lipworth B.; Louis R.; Makris M.; Monti R.; Morais-Almeida M.; Mösges R.; Mullol J.; Odemyr M.; Okamoto Y.; Papadopoulos N.G.; Patella V.; Pham-Thi N.; Regateiro F.S.; Reitsma S.; Rouadi P.W.; Samolinski B.; Sova M.; Todo-Bom A.; Taborda-Barata L.; Tomazic P.V.; Toppila-Salmi S.; Sastre J.; Tsiligianni I.; Valiulis A.; Wallace D.; Waserman S.; Yorgancioglu A.; Zidarn M.; Zuberbier T.; Fonseca J.A.; Bousquet J.; Pfaar O.
    Background: Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real-life studies. Objective: To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK-air® app: those receiving sublingual AIT (SLIT), those receiving subcutaneous AIT (SCIT), and those receiving no AIT. Methods: We assessed the MASK-air® data of European users with self-reported grass pollen allergy, comparing the data reported by patients receiving SLIT, SCIT and no AIT. Outcome variables included the daily impact of allergy symptoms globally and on work (measured by visual analogue scales—VASs), and a combined symptom-medication score (CSMS). We applied Bayesian mixed-effects models, with clustering by patient, country and pollen season. Results: We analysed a total of 42,756 days from 1,093 grass allergy patients, including 18,479 days of users under AIT. Compared to no AIT, SCIT was associated with similar VAS levels and CSMS. Compared to no AIT, SLIT-tablet was associated with lower values of VAS global allergy symptoms (average difference = 7.5 units out of 100; 95% credible interval [95%CrI] = −12.1;−2.8), lower VAS Work (average difference = 5.0; 95%CrI = −8.5;−1.5), and a lower CSMS (average difference = 3.7; 95%CrI = −9.3;2.2). When compared to SCIT, SLIT-tablet was associated with lower VAS global allergy symptoms (average difference = 10.2; 95%CrI = −17.2;−2.8), lower VAS Work (average difference = 7.8; 95%CrI = −15.1;0.2), and a lower CSMS (average difference = 9.3; 95%CrI = −18.5;0.2). Conclusion: In patients with grass pollen allergy, SLIT-tablet, when compared to no AIT and to SCIT, is associated with lower reported symptom severity. Future longitudinal studies following internationally-harmonised standards for performing and reporting real-world data in AIT are needed to better understand its ‘real-world’ effectiveness. © 2022 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
  • No Thumbnail Available
    Item
    Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air® real-world data
    (John Wiley and Sons Inc, 2022) Sousa-Pinto B.; Sá-Sousa A.; Vieira R.J.; Amaral R.; Klimek L.; Czarlewski W.; Antó J.M.; Pfaar O.; Bedbrook A.; Kvedariene V.; Ventura M.T.; Ansotegui I.J.; Bergmann K.-C.; Brussino L.; Canonica G.W.; Cardona V.; Carreiro-Martins P.; Casale T.; Cecchi L.; Chivato T.; Chu D.K.; Cingi C.; Costa E.M.; Cruz A.A.; De Feo G.; Devillier P.; Fokkens W.J.; Gaga M.; Gemicioğlu B.; Haahtela T.; Ivancevich J.C.; Ispayeva Z.; Jutel M.; Kuna P.; Kaidashev I.; Kraxner H.; Larenas-Linnemann D.E.; Laune D.; Lipworth B.; Louis R.; Makris M.; Monti R.; Morais-Almeida M.; Mösges R.; Mullol J.; Odemyr M.; Okamoto Y.; Papadopoulos N.G.; Patella V.; Pham-Thi N.; Regateiro F.S.; Reitsma S.; Rouadi P.W.; Samolinski B.; Sova M.; Todo-Bom A.; Taborda-Barata L.; Tomazic P.V.; Toppila-Salmi S.; Sastre J.; Tsiligianni I.; Valiulis A.; Vandenplas O.; Wallace D.; Waserman S.; Yorgancioglu A.; Zidarn M.; Zuberbier T.; Fonseca J.A.; Bousquet J.
    Background: Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data. Methods: We analysed 2015–2020 MASK-air® European data. We compared days under no medication, monotherapy and co-medication using the visual analogue scale (VAS) levels for overall allergic symptoms (‘VAS Global Symptoms’) and impact of AR on work. We assessed the monthly use of different medication schemes, performing separate analyses by region (defined geographically or by Google Trends patterns). We estimated the average number of different drugs reported per patient within 1 year. Results: We analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy and 38,315 (17.3%) under co-medication. The median ‘VAS Global Symptoms’ was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p <.001). Medication use peaked during the spring, with similar patterns across different European regions (defined geographically or by Google Trends). Oral H1-antihistamines were the most common medication in single and co-medication. Each patient reported using an annual average of 2.7 drugs, with 80% reporting two or more. Conclusions: Allergic rhinitis medication patterns are similar across European regions. One third of treatment days involved co-medication. These findings suggest that patients treat themselves according to their symptoms (irrespective of how they understand AR) and that co-medication use is driven by symptom severity. © 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
  • No Thumbnail Available
    Item
    Important steps towards a big change for lung health: a joint approach by the European Respiratory Society, the European Society of Radiology and their partners to facilitate implementation of the European Union’s new recommendations on lung cancer screening
    (European Respiratory Society, 2023) Ward B.; Vašáková M.K.; Cordeiro C.R.; Yorgancioğlu A.; Chorostowska-Wynimko J.; Blum T.G.; Kauczor H.-U.; Samarzija M.; Henschke C.; Wheelock C.; Grigg J.; Andersen Z.J.; Koblížek V.; Májek O.; Odemyr M.; Powell P.; Seijo L.M.
    [No abstract available]